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Background: AmpC or class C or group 1 beta lactamases are class C cephalosporinases that hydrolyse a wide 
variety of beta-lactam antibiotics including alpha methoxy beta-lactams (cefoxitin), narrow and broad spectrum 
cephalosporins. This study was conducted to characterize plasmid-mediated AmpC producing enteric Gram- 
negative bacteria from patients with lower respiratory tract infections in Obafemi Awolowo University Teaching 
Hospital Complex (OAUTHC) Ile Ife, Osun State, Nigeria   
Methodology: A total of 149 patients with clinical features of lower respiratory tract infections (LRTI) were 
selected by simple random sampling for the study. All Gram-negative isolates recovered from standard 
microbiological cultures of respiratory specimens of these patients were tested against cefoxitin, third generation 
cephalosporins (3GCs), and other antibiotics using the disc diffusion AST method, and also screened for 
production of AmpC beta-lactamases phenotypically by the CLSI method. Plasmid DNA extraction was carried out 
on twenty-nine cefoxitin-resistant selected isolates using the Kado and Lin method, while genotypic detection of 
plasmid-mediated AmpC gene was carried out by the polymerase chain reaction (PCR) assay.  
Results: The results showed that 204 (43.3%) of 471 isolates recovered from the 149 selected patients were 
resistant to 3GC in the AST assay, among which 121 (59.3%) were resistant to cefoxitin, and 189 of the 471 
isolates (40.1%) were AmpC producers. The AmpC producers concurrently showed multiple resistance pattern to 
other antibiotics tested in this study. Ninety six percent of the 29 selected isolates for plasmid analysis contained 
plasmids, 45% of which amplified positive on PCR for CMY, 38% for FOX, and 31% for ACC types of AmpC genes.  
Conclusion: This study showed a high degree of antibiotic resistance among enteric Gram-negative bacteria 
recovered from patients with LRTIs, as well as high degree of plasmid-encoded AmpC genes responsible for this 
high antibiotic resistance among the isolates. Proper antibiotic policy and regulation are required to limit the 
spread of plasmid mediated AmpC β-lactamase producing organisms because they can lead to therapeutic failure 
in infected patients in the nearest future. 
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Contexte: Les bêta-lactamases AmpC ou de classe C ou de groupe 1 sont des céphalosporinases de classe C qui 
hydrolysent une grande variété d'antibiotiques bêta-lactamines, y compris les alpha-méthoxy bêta-lactamines 
(céfoxitine), les céphalosporines à spectre étroit et large. Cette étude a été menée pour caractériser les bactéries 
à Gram négatif entériques produisant de l'AmpC à médiation plasmidique chez des patients atteints d'infections 
des voies respiratoires inférieures du complexe hospitalier universitaire d'Obafemi Awolowo (OAUTHC) Ile Ife, 
État d'Osun, Nigéria                                                          
Méthodologie: Un total de 149 patients présentant des caractéristiques cliniques d'infections des voies 
respiratoires inférieures (LRTI) ont été sélectionnés par échantillonnage aléatoire simple pour l'étude. Tous les 
isolats à Gram négatif récupérés à partir de cultures microbiologique standard d'échantillons respiratoires de ces 
patients ont été testés contre la céfoxitine, les céphalosporines de troisième génération (3GC) et d'autres 
antibiotiques en utilisant la méthode AST de diffusion sur disque, et également criblés pour la production de bêta-
lactamases AmpC phénotypiquement par le Méthode CLSI. L'extraction de l'ADN plasmidique a été réalisée sur 
29 isolats sélectionnés résistants à la céfoxitine en utilisant la méthode Kado et Lin, tandis que la détection 
génotypique du gène AmpC à médiation plasmidique a été réalisée par le test de réaction en chaîne par 
polymérase (PCR).                             
Résultats: Les résultats ont montré que 204 (43,3%) des 471 isolats récupérés des 149 patients sélectionnés 
étaient résistants à la 3GC dans le test AST, parmi lesquels 121 (59,3%) étaient résistants à la céfoxitine et 189 
des 471 isolats (40,1%) étaient des producteurs d'AmpC. Les producteurs d'AmpC ont montré simultanément 
plusieurs profils de résistance à d'autres antibiotiques testés dans cette étude. Quatre-vingt-seize pour cent des 
29 isolats sélectionnés pour l'analyse des plasmides contenaient des plasmides, dont 45% amplifiés positifs par 
PCR pour CMY, 38% pour FOX et 31% pour les types ACC des gènes AmpC.                  
Conclusion: Cette étude a montré un degré élevé de résistance aux antibiotiques parmi les bactéries entériques 
Gram-négatives récupérées chez des patients atteints de LRTI, ainsi qu'un degré élevé de gènes AmpC codés par 
plasmide responsable de cette résistance élevée aux antibiotiques parmi les isolats. Une politique et une 
réglementation appropriées en matière d'antibiotiques sont nécessaires pour limiter la propagation des 
organismes producteurs β-lactamase d'AmpC à médiation plasmidique car ils peuvent conduire à un échec 
thérapeutique chez les patients infectés dans un avenir proche. 




 The resistance rate of multidrug-resis- 
tant (MDR) Gram-negative bacteria has incr- 
eased continuously in the past few years, and 
bacterial strains that produce AmpC-type or 
class C beta-lactamases and the extended 
spectrum beta-lactamases (ESBLs) are now of 
concern (1). However, the increased presence 
of plasmid-mediated AmpC beta-lactamases in 
the world is becoming of greater concern. 
Gram-negative organisms resistant to carba- 
penems or third generation cephalosporins 
due to ESBL production were defined as highly 
resistant isolates. However, strains resistant 
to two or more agents of the antimicrobial 
classes (e. g. quinolone and aminoglycoside) 
were also defined as highly resistant strains 
(2).     
 AmpC-type beta-lactamases are cep- 
halosporinases that hydrolyze cephamycins as 
well as other extended-spectrum cephalo- 
sporins and are poorly inhibited by clavulanic 
acid. They are clinically significant because 
they confer resistance to groups of antibiotics 
such as cephalosporin, penicillin, cephamycin 
and monobactam. The AmpC gene located on 
plasmids or chromosomes can be moved from 
one microorganism to another through trans- 
formation and conjugation. The presence of 
such genes on plasmids facilitates their spread 
between the family of Enterobacteriaceae (3). 
The AmpC enzyme-producing strains show 
broader and higher resistance, making them 
more challenging for physicians to treat asso- 
ciated infections by such strains.  
 There are two types of AmpC β-
lactamases; plasmid-mediated (usually cons- 
titutive and rarely inducible) and chromosomal 
mediated (inducible). The chromosomal AmpC 
enzymes are communicated constitutively at a 
low level and are constantly found in bacteria 
such as Citrobacter freundii, Enterobacter 
cloacae, Morganella morganii, Hafnia alvei and 
Serratia marcescens. They are inducible nor- 
mally by β-lactam antimicrobial agents such 
as cefoxitin and imipenem which are inter- 
ceded by the AmpR regulator. However, they 
are inadequately induced by the third or fourth 
generation cephalosporins (4,5). Infections 
caused by AmpC producing bacteria are of 
particular clinical and epidemiological impor- 
tance, and are often associated with high 
morbidity and mortality in infected patients 
(6,7).    
 Plasmid-mediated AmpC beta-lacta- 
mases (PMACBL) have been found all over the 
world but are much less common than ESBLs 
(5,8). Most strains of PMACBL have been isola- 
ted from patients after several days of hosp- 
italization, but culture of the isolates from 
long-term care facilities, rehabilitation cen- 
ters, and outpatient clinics have been reported 
(9,10). Risk factors for bloodstream infection 
(BSI) caused by AmpC producing strains of 
Klebsiella pneumoniae and other enteric 
pathogens include prolonged hospital stay, 
care in an emergency unit, central venous 




catheterization, indwelling urinary catheter, 
and administration of broad spectrum cepha- 
losporins and beta-lactamase inhibitors, which 
are similar risk factors for infections caused by 
ESBL producing K. pneumoniae strains (5,11, 
12).      
 There is paucity of data on the preva- 
lence of AmpC beta-lactamases among Gram 
negative isolates in Ile-Ife, Nigeria. Hence this 
study aimed to determine the prevalence and 
characterize AmpC producing Gram-negative 
enteric bacteria isolates from patients with 
lower respiratory tract infections (LRTI) in 
Obafemi Awolowo University Teaching Hos- 
pital Complex (OAUTHC) Ile-Ife, Nigeria. 
 
Materials and method: 
 
Study setting, design and sampling  
 Patients who reported at the Obafemi 
Awolowo University Teaching Hospital Com- 
plex (OAUTHC) chest clinic, adult emergency 
and chronic obstructive pulmonary disease 
(COPD) clinic with symptoms of lower respi- 
ratory tract infections were selected by simple 
random sampling and recruited for this study. 
Sputum and nasal swabs samples were colle- 
cted aseptically from subjects between the 
period of January, 2015 and February, 2016. 




 Ethical approval was obtained from 
the Hospital Ethical and Research Committee 
of the institution. Informed consent of each 
subject was also obtained. 
 
Specimen collection, processing and bacterial 
isolation  
 Sputum and nasal swabs of selected 
subjects with lower respiratory infections were 
collected into sterile universal bottles and 
sterile swab sticks respectively. The samples 
were cultured on cetrimide agar medium and 
MacConkey agar (Oxoid Ltd., Basingstoke, UK) 
and incubated aerobically at 37°C for 18–24 h. 
Bacteria growth colonies on the culture plates 
were identified microbiologically using conv- 
entional methods (colonial morphology, Gram 
staining, and biochemical tests) according to 
Cheesebrough (13) and confirmed by the API 
20E commercial identification kit.  
 
Antibiotic susceptibility test (AST) 
 Antibiotic susceptibility testing (AST) 
was performed by the Kirby Bauer disc diffu- 
sion method. Mueller-Hinton (MH) agar plates 
were inoculated with 18-24 h culture inoculum 
of each bacterial isolate standardized with 0.5 
McFarland standards. Single antibiotics discs 
(Oxoid, Basingstoke, Hampshire, England) of; 
cefotaxime (30µg), piperacillin (10µg), aug- 
mentin (2µg), cefoxitin (30µg), ceftazidime 
(30µg), cefuroxime (30µg), ceftriaxone (30 
µg), ofloxacin (5µg), cefixime (5µg), imipe- 
nem (10µg), gentamicin (10µg), ciprofloxacin 
(5µg) and nitrofurantoin (300µg) were firmly 
placed on the surface of the inoculated MH 
agar plate using a sterile forcep. The plates 
were incubated aerobically in an inverted posi- 
tion at 37oC for 18–24 h. The diameters of 
zone of inhibition of each bacterial isolate to 
each antibiotic disk on the culture plate was 
measured and compared with the Clinical and 
Laboratory Standards Institute (CLSI) guide- 
lines (14) to determine resistivity or resistance 
of each isolate. 
 
Screening of AmpC production 
 The primary screening of the AmpC 
enzyme-producing strains was conducted by 
the Kirby-Bauer disk diffusion method descri- 
bed by Kazemian (15). AmpC-producing bac- 
teria were detected using FOX (30µg) drug-
sensitive disc according to the CLSI standards. 
A clear zone of ≤18 mm indicated strains pro- 
ducing AmpC enzyme (16).  
 
Extraction of plasmid DNA 
 Plasmid DNA extraction was carried 
out according to the method of El-deeb (17), 
and Ganesh et al, (18). The plasmid DNA of 29 
selected cefoxitin resistant Klebsiella isolates 
was extracted by suspending the bacterial cell 
in an Eppendorf tubes containing 1ml of sterile 
distilled water. The tube was then vortex- 
mixed and centrifuged at 13,000 rpm for 5 min 
using BIO-RAD model 16K micro-centrifuge, 
and the supernatant was decanted. A 200µl of 
lysing solution (Tris buffer and 0.1% sodium 
dodecyl sulfate) was added to the pellet and 
the cell pellet was re-suspended completely to 
achieve complete lysis (17,18). The cell pellet 
was incubated at 65oC for 30 minutes.  
 Phenol-chloroform (1:1) solution (200 
µl) was added to the pellet and mixed by inv- 
ersion until complete emulsion is formed so as 
to precipitate the protein and to remove the 
cell debris (17). The tube was then centrifuged 
at high speed for 10 minutes. One hundred 
and fifty microliters (150µl) of the supernatant 
were transferred into a fresh tube and mixed 
well with 3µl of 5M NaCl and 150µl propanol 
was added to the tube to precipitate the DNA 
and mixed by inverting the tubes 3-5 times 
until the mixture became sticky. Samples were 
kept on ice for 20 minutes (to prevent them 
from the degradation of chromosomal DNA 
which may be co-precipitated with plasmid) 
and spinned at 12,000 rpm for 20 minutes and 
the supernatant was removed immediately. A 
100µl of cold 80% ethanol was added to wash 
the DNA and spinned at 12000 rpm for 3 min, 
the supernatant was immediately removed. 
The pellet was then dried completely and re-
suspended in 30μl of TE (Tris Ethylene diamine 
tetraacetate) buffer or distilled water and 




RNase (to degrade RNA) for further use. 
 Purified plasmids were electropho- 
resed in 0.8% (w/v) agarose for size esti- 
mation and pattern comparison. Plasmid DNA 
bands were visualized by UV-transilluminator, 
photographed with a Polaroid camera and doc- 
umented using a gel electrophoresis docum-              
entation system. The molecular sizes of the 
unknown plasmid DNA were then estimated by 
comparing the distance travelled with that of 
the molecular weight of the standards (17,18). 
Molecular detection of AmpC beta-lactamase 
genes by PCR assay 
 The extracted plasmid DNA served as 
the PCR template. The genes encoding the 
PMACBL in cefoxitin-resistant Klebsiella isola- 
tes were detected by PCR technique (19). The 
PCR was performed using 25 μl of AmpliTaq 
Gold PCR Master Mix (Applied Biosystems), 
0.5 μM of the forward and reversed primers for 
ACC-M-F-AACAGCCTCAGCAGCCGGTTA, ACC-
M-R-TTCGCCGCAATCATCCCTAGC (346bp), and 
CMY-F-TGGCCAGAACTGACAGGCAAA, CMY-R-
TTTCTCCTGAACGTGGCTGGC (462bp), 0.4 μM 
of the primers for FOX-M-F-AACATGGGG TAT 
CAGGGAGATG, and FOX-M-R-CAAAGCGCGTA 
ACCGGATTGG (190bp) (20), and 2μl of plasmid 
DNA template. The final reaction volume of 
50μl was made up with sterile distilled water. 
 The amplification conditions were 10 
min at 95oC; 25 cycles of 94oC for 30 s, 64oC 
for 30, 72oC for 60 s; and final extension of 
72oC for 7 minutes. The amplicons were elec- 
trophoresed on 0.8% (w/v) agarose, and 
bands were visualized with ultraviolet trans-
illuminator and photographed using gene gel 
bioimaging system.  
 
Statistical analysis 
 The data obtained were analysed 
using GraphPad Prism Version 6.01. The Chi-
square test was used to test the significance 
of association of the variables with p < 0.05 




 The baseline characteristics of the 149 
patients are depicted in Table 1. From the 471 
isolates recovered, 40% (189/471) were 
AmpC producers, with the most frequent iso- 
lates being Enterobacter sp (66.6%, 42/63), 
followed by Yersinia sp (60%, 6/10) and the 
least is Escherichia coli (12.1%, 4/33) (Table 
2). The isolates were most resistant to peni- 
cillins (100%), cephems (51.9%), beta-lactam 
inhibitors (76.6%), and least resistant to flu- 
oroquinolones (4.4%) (Table 3). The multiple 
antibiotic resistance (MAR) phenotypes of the 
bacterial isolates showed that diversities of 
MAR patterns occurred among the isolates of 
which 0.75% and 0.25% developed resistance 
to six and seven classes of antibiotics tested 
respectively, 5.5% developed resistance to 
five classes of antibiotics, 21.6% to four and 
65.3% to three classes of antibiotics. All 
isolates exhibited different resistance profiles 
with “AMCR/AUGR/PRLR” appearing the most 
frequent. 
 Ninety-six percent (96%) of the selec- 
ted cefoxitin resistant and AmpC producing 
Klebsiella (n=29) isolates harboured single 
plasmid with molecular weight of 1300 bp. The 
PCR result showed that 13 (45%) of the 29 
isolates were positive for CMY gene, 11 (38%) 
amplified for FOX gene while only 9 (31%) 




 The results of the plasmid DNA anal- 
ysis showed that the representatives multiple 
antibiotic resistant isolates harboured single 
plasmid. Ganesh et al., (18) reported similar 
single plasmid in E. coli. Plasmids are environ- 
mental and genetic factors that are highly 
mobile and can confer resistance genes on 
several classes of antimicrobials. The preva- 
lence of plasmid-mediated AmpC type resis- 
tance is imperative to give helpful data and 
information expected to focused antimicrobial 
treatment and better disease control (21). The 
isolates were highly resistant to third gene- 
ration cephalosporins including cefoxitin as 
previously reported by Thonda et al., (22). 
Reasons may be that the third generation 
cephalosporins antibiotics have been misused 
for a long period by individuals, therefore, 
over time the pathogens have developed 
resistance to these antibiotics (22). 
 In this study, 40% of the isolates were 
producers of PMACBL. AmpC production in 
these isolates could be due to a mechanism 
similar to that of ESBL producing organism 
that appear susceptible to ceftazidime by the 
disc diffusion method. This finding is similar to 
the study of Manchanda and Singh (23) who 
reported 39% cefoxitin susceptibility in AmpC   
producers. Our study showed that not all 
cefoxitin resistant isolates possess plasmid 
AmpC β-lactamase gene by PCR assay. This 
finding agreed with the study of Fam et al., 
(24) and Yilmaz et al., (25) which reported 
that not all cefoxitin resistant isolates are 
AmpC β-lactamase producers. Firstly, the rea- 
son may be because cefoxitin resistance is not 
due to production of AmpC β-lactamase but 
also may be as a result of other enzymatic 
mechanism such as extended spectrum beta 
lactamases (ESBLs) and metallo beta-lacta- 
mase (MBL) or because of the non-enzymatic 
mechanism such as porin channel mutation 
(26). Another reason may be cefoxitin resis- 
tant phenotype in E. coli can result from over- 
expression  of  the  chromosomal  AmpC gene 




Table 1: Socio-demographic and clinical characteristics of patients with lower respiratory tract infections in Obafemi Awolowo 
University Teaching Hospital Complex (OAUTHC), Ile-Ife, Nigeria 
 OAUTHC = Obafemi Awolowo University Teaching Hospital Complex; SDA = Seventh Day Adventist Hospital 
 
Table 2: Prevalence and distribution of AmpC producing enteric Gram-negative bacteria isolates in Obafemi Awolowo University 
Teaching Hospital Complex (OAUTHC), Ile-Ife, Nigeria 
 
 3GC = 3rd generation cephalosporins 
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Isolated Organism No of isolates 
resistant to 3GC 
No of AmpC positive Isolates 
(%) 
Enterobacter sp (n=63) 21 42 (66.6) 
Klebsiella sp (n=166) 116 50 (30.1) 
P. aeruginosa (n=47) 20 27 (57.5) 
Escherichia coli (n=33) 29 4 (12.1) 
Serratia sp (n=20) 13 7 (35) 
Aeromonas sp (n=29) 16 13 (44.8) 
Citrobacter sp (n=37) 25 12 (32.4) 
Salmonella sp (n=32) 17 15 (46.9) 
Providencia sp (n=4) 3 1 (25) 
Yersinia sp (n=10) 4 6 (60) 
Shigella sp (n=28) 16 12 (42.9) 
Total (n=471) 204 (43.3) 189 (40.1) 







































































































































100 51.9 76.6 4.4 15.9 12.3 3.92 
       Piperacillin-PRL, Cefotaxime-CTX, AMC-Amoxicillin-clavulanic acid, Imipenem-IPM, Nitrofurantoin-NIT, Ofloxacin-OFL, Gentamicin-GEN 
 
        
Lane N=DNA Ladder (100bp), Lane A-M = Positive for CMY gene 
 






Lane L=DNA Ladder (100bp), Lane 1-13 = Positive for FOX gene 
 




500 bp  
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Lane L=DNA Ladder (100bp), Lane 1-13 = Positive for ACC gene 
 
Fig 3: Agarose gel electrophoresis of the amplification product coding ACC gene (346bp) in selected multiple antibiotic resistant 
Klebsiella isolates 
 
because of mutations that could occur in the 
promoter and attenuator regions (27). Cefo- 
xitin has been demonstrated as a substrate to 
active efflux pump in clinical isolates (28). 
Genes for AmpC beta-lactamases are com- 
monly found among members of the family 
Enterobacteriaceae including Enterobacter sp, 
Shigella, Providencia, Citrobacter freundii, 
Morganella morganii, Serratia marcescens and 
E. coli.     
 In this study, PCR revealed CMY genes 
to be the most prevalent among the AmpC 
genes. The prevalence rate was similar to the 
study of Soha and Lamina (5), which reported 
Klebsiella sp to be 44% AmpC producers, but 
much lower than the study of Wassef et al., 
(39), which reported that 26.9% harboured 
the plasmid-mediated AmpC gene and that of 
Yilmaz et al., (25) who reported that 3.6% K. 
pneumoniae were AmpC-producing strains. 
The molecular detection of plasmid- mediated 
AmpC using PCR techniques showed that the 
most prevalent AmpC gene belongs to family 
CMY which was detected in 40% of all sele- 
cted isolates tested while FOX and ACC genes 
were 33% and 27% respectively. Cefoxitin 
resistance in non-AmpC producers could be 
due to some other resistance mechanism(s). 
Hernandez-Alles et al., (30) have demons- 
trated the interruption of a porin gene by ins- 
ertion sequences which could be a common 
type of mutation which causes loss of porin 
expression and high cefoxitin resistance in K. 
pneumoniae.     
 The results of the present study indi- 
cate that screening should include all the 
clinical isolates showing resistance to any of 
the cephalosporins irrespective of their cefo- 
xitin susceptibility status. Plasmid-mediated 
AmpC beta-lactamases may have arisen thr- 
ough the transfer of chromosomal genes for 
the inducible AmpC beta-lactamases onto pla- 
smids. This transfer has resulted in plasmid-
mediated AmpC beta-lactamases in isolates of 
E. coli, K. pneumoniae, Salmonella sp, Citro- 
bacter freundii, Enterobacter aerogenes and 
Proteus mirabilis. AmpC beta-lactamase prod- 
ucing bacterial pathogens may cause a major 
therapeutic failure if not detected and reported 
in time.  
Conclusion: 
 
 In our study, the prevalence of AmpC 
beta-lactamase resistance is high among pati- 
ents with respiratory infection and who had 
prior exposure to antibiotics. Detection and 
identification of types of PMACBL producing 
organisms is also important to ensure effective 
therapeutic intervention and optimal clinical 
outcomes so as to aid in hospital infection 
control and to help the clinicians to prescribe 
the most appropriate therapeutic agents, 
thereby decreasing the selective pressure, 
which generates antibiotic resistance. 
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